Bone Diseases, Metabolic

The grounding supports multiple causes across metabolic bone diseases rather than a single etiology. In premature infants, inadequate prenatal and postnatal calcium and phosphate accretion is a defined cause of metabolic bone disease of prematurity. More broadly, altered gut microbiota composition and host responses, sex chromosome abnormalities, and steroid hormones are described as contributors to pathological bone loss or osteoporosis.

The literature describes an imbalance between bone anabolic and resorptive processes as a central mechanism in metabolic bone disorders. A key pathway in bone resorption is the OPG/RANKL/RANK system, which is identified as the dominant final mediator of osteoclastogenesis. Gut-derived metabolites, especially short-chain fatty acids, are also described as regulators of bone cells and bone health, linking the microbiome to skeletal metabolism.

Prematurity is a risk factor for metabolic bone disease of prematurity because mineral accretion is inadequate ex utero. Female sex is described as a susceptibility factor for osteoporosis, while males are noted to be more prone to disability or death from the disease. Alterations in microbiota composition and host responses, as well as sex-specific hormonal and chromosomal influences, are also associated with increased risk of pathological bone loss.

Treatment is described at the level of nutritional and pharmacologic categories rather than specific regimens. For metabolic bone disease of prematurity, monitoring with serum calcium, phosphorus, and alkaline phosphatase is used to identify infants at risk, and prevention or treatment focuses on calcium and phosphate repletion to support mineral accretion. For broader metabolic bone disorders, the grounding indicates that drugs are available to address bone metabolic pathology, and that prebiotics and probiotics may be used to modify microbiota-related bone loss.